EICHORPublic-registry site landscape for NCT07702032, “Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer”, a Left-sided Colorectal Cancer study sponsored by Genmab. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07702032 (registry record) |
| Study title | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer |
| Official title | A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer |
| Sponsor | Genmab |
| Condition(s) | Left-sided Colorectal Cancer |
| Phase | PHASE3 |
| Listed sites | 0 |
| Intervention(s) | Petosemtamab, Cetuximab, FOLFIRI, mFOLFOX6 |
Patient-friendly overview of this study: eichor.com/study/NCT07702032.
Eichor generates a preliminary site-risk snapshot for NCT07702032 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
